期刊文献+

多发性骨髓瘤骨病骨代谢物研究进展 被引量:1

The bone turnover markers of myeloma bone disease
原文传递
导出
摘要 多发性骨髓瘤(MM)是恶性浆细胞克隆性疾病.恶性浆细胞可侵犯全身骨骼系统,导致骨髓瘤骨病(MBD)的发生.溶骨性骨病、广泛骨质疏松、严重骨痛、病理性骨折和高钙血症是MBD的主要临床表现,目前MBD的诊断主要依靠影像学检查,但影像学检查发现有骨骼异常时MBD大多已处于中晚期,呈不可逆状态,治疗难度很大,近年研究显示血液/尿中某些骨代谢物水平与骨破坏相关,并能较影像学检查更早地发现MBD。
作者 彭凤平 付蓉
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第11期1030-1033,共4页 Chinese Journal of Hematology
基金 天津市抗癌重大专项攻关计划(12ZCDZSY18000)
  • 相关文献

参考文献28

  • 1Roodman GD. Pathogenesis of myeloma bone disease [J]. Leukemia, 2009, 23 (3):435-441.
  • 2Samani KK, Brazier M, Mathiot C, et al. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma[J]. Ann Hematol, 2005, 84( 1 ):19-24.
  • 3Terpos E, de la Fuente J, Szydlo R, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma [J]. Int J Cancer, 2003,106 (3) :455 -457.
  • 4Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease [J]. Leukemia, 2010, 24 (5):1043 - 1049.
  • 5Dizdar O, Barista I, Kalyoncu U, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease [J]. Am J Hematol, 2007, 82(3):185-191.
  • 6Djunic I, Elezovic I, Marinkovic M, et al. Osteolytic lesions marker in multiple myeloma [J]. Med Oncol, 2011, 28 (1):237- 240.
  • 7Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemi- cal markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group [ J]. Leukemia, 2010, 24( 10): 1700-1712.
  • 8Lipton A, Cook RJ, Coleman RE, et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma [J]. Clin Lymphoma Myeloma, 2007, 7 (5): 346-353.
  • 9鲍立,黄晓军.多发性骨髓瘤骨病患者骨代谢及调节因子水平及其意义[J].中华内科杂志,2011,50(3):243-247. 被引量:7
  • 10Tu Q, Zhang J, Fix A, et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells [J]. J Cell Physiol, 2009, 218( 1 ): 135-145.

二级参考文献58

  • 1谢晓冬,刘永叶,郑振东,高雅玲,李京宁,郑宏柱,刘大为,单学健,邢春景.晚期恶性肿瘤骨转移患者治疗的临床研究[J].中国实用内科杂志,2005,25(2):127-129. 被引量:20
  • 2段红光,倪家骧.疼痛的定性与定量测量[J].辽宁医学杂志,1996,10(1):1-2. 被引量:48
  • 3Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995, 10:1478-1487.
  • 4Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse maerophage-like ceils in vitro by a nitric oxideindependent mechanism. J Bone Miner Res, 1996, 11: 1482-1491.
  • 5Rosen LS, Cordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disadium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98 : 1735-1744.
  • 6Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronie acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized triM. J Clin Oncol, 2003, 21:3150-3157.
  • 7Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002, 94 : 1458-1468.
  • 8Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 2005, 23:3314-3321.
  • 9Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer, 2000, 88:2919-2926.
  • 10Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev, 2001, 27 : 181-185.

共引文献29

同被引文献8

引证文献1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部